Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (Nasdaq: LGND) concerning possible violations of federal securities laws. If you purchased or otherwise acquired Ligand shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm's website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org. This investigation focuses on whether Ligand and certain of its directors and/or officers violated federal securities laws. On November 9, 2016, Ligand announced that it would not be able to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 and that it was reviewing a potential restatement. On November 14, 2016, the Company announced that it would restate financial statements for the quarters ended September 30, 2015; December 31, 2015; March 31, 2016; and June 30, 2016, due to a material error. Ligand also disclosed that its management determined that the Company did not maintain effective controls over the accuracy and presentation of accounting for income taxes related to complex transactions. If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.